BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pemazyre (Pemigatinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pemazyre (Pemigatinib)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04659616-2225@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pemazyre (Pemigatinib): Phase 1 readout est. (NCT04659616)
DESCRIPTION:Pemazyre (Pemigatinib)\, phase 1.\nStudy: Pemigatinib After Che
 motherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia\nEst
 imated primary completion: 31 December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pemigatinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04659616
URL:https://assetmemo.bio/drug/pemigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06906562-2225@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pemazyre (Pemigatinib): Phase 2 readout est. (NCT06906562)
DESCRIPTION:Pemazyre (Pemigatinib)\, phase 2.\nStudy: A Phase II Nationwide
 \, Fully Decentralized\, Telemedicine Study of Pemigatinib in Adult Patien
 ts With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterat
 ions\nEstimated primary completion: 31 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pemigatinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06906562
URL:https://assetmemo.bio/drug/pemigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06653777-2225@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pemazyre (Pemigatinib): Phase 2 readout est. (NCT06653777)
DESCRIPTION:Pemazyre (Pemigatinib)\, phase 2.\nStudy: Efficacy of Pemigatin
 ib in Patients With Solid Tumors Characterized by an Alteration of the Gen
 e FGFR in Tumor Cells\nEstimated primary completion: 30 June 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pemigatinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06653777
URL:https://assetmemo.bio/drug/pemigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06728410-2225@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pemazyre (Pemigatinib): Phase 2 readout est. (NCT06728410)
DESCRIPTION:Pemazyre (Pemigatinib)\, phase 2\, Cholangiocarcinoma.\nStudy: 
 A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Adva
 nced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearra
 ngement\nEstimated primary completion: July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pemigatinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06728410
URL:https://assetmemo.bio/drug/pemigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-2225@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Pemazyre (Pemigatinib): Phase 2 readout est. (NCT02925234)
DESCRIPTION:Pemazyre (Pemigatinib)\, phase 2.\nStudy: The Drug Rediscovery 
 Protocol (DRUP Trial)\nEstimated primary completion: September 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pemigatinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/pemigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06302621-2225@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Pemazyre (Pemigatinib): Phase 1 readout est. (NCT06302621)
DESCRIPTION:Pemazyre (Pemigatinib)\, phase 1\, Cholangiocarcinoma.\nStudy: 
 Pemigatinib + Afatinib in Advanced Refractory Solid Tumors\nEstimated prim
 ary completion: 1 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pemigatinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06302621
URL:https://assetmemo.bio/drug/pemigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07786766-2225@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pemazyre (Pemigatinib): Phase 2 readout est. (NCT07786766)
DESCRIPTION:Pemazyre (Pemigatinib)\, phase 2\, Cholangiocarcinoma.\nStudy: 
 Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusi
 on/Rearrangement-Positive Cholangiocarcinoma\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 emigatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07786766
URL:https://assetmemo.bio/drug/pemigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06389799-2225@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pemazyre (Pemigatinib): Phase 2 readout est. (NCT06389799)
DESCRIPTION:Pemazyre (Pemigatinib)\, phase 2.\nStudy: A Phase 2\, Open Labe
 l Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIpos
 arcoma (PERELI)\nEstimated primary completion: 31 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pemigatinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06389799
URL:https://assetmemo.bio/drug/pemigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07780838-2225@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pemazyre (Pemigatinib): Phase 2 readout est. (NCT07780838)
DESCRIPTION:Pemazyre (Pemigatinib)\, phase 2\, Cholangiocarcinoma.\nStudy: 
 Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Bilia
 ry or Cholangiocarcinoma\nEstimated primary completion: 31 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pemigatinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07780838
URL:https://assetmemo.bio/drug/pemigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439485-2225@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20280222
DTEND;VALUE=DATE:20280223
SUMMARY:Pemazyre (Pemigatinib): Phase 1/2 readout est. (NCT06439485)
DESCRIPTION:Pemazyre (Pemigatinib)\, phase 1/2\, Cholangiocarcinoma.\nStudy
 : Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bev
 acizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion\nE
 stimated primary completion: 22 February 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pemigatinib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06439485
URL:https://assetmemo.bio/drug/pemigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07434843-2225@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Pemazyre (Pemigatinib): Phase 2 readout est. (NCT07434843)
DESCRIPTION:Pemazyre (Pemigatinib)\, phase 2.\nStudy: PH 2 Pemigatinib in S
 DH-deficient GIST\nEstimated primary completion: 1 October 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pemigatinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07434843
URL:https://assetmemo.bio/drug/pemigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07862998-2225@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20310225
DTEND;VALUE=DATE:20310226
SUMMARY:Pemazyre (Pemigatinib): Phase 2 readout est. (NCT07862998)
DESCRIPTION:Pemazyre (Pemigatinib)\, phase 2\, Cholangiocarcinoma.\nStudy: 
 A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants
  With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Wi
 th FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic 
 Therapy\nEstimated primary completion: 25 February 2031. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pemigatinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07862998
URL:https://assetmemo.bio/drug/pemigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05159245-2225@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20311125
DTEND;VALUE=DATE:20311126
SUMMARY:Pemazyre (Pemigatinib): Phase 2 readout est. (NCT05159245)
DESCRIPTION:Pemazyre (Pemigatinib)\, phase 2.\nStudy: The Finnish National 
 Study to Facilitate Patient Access to Targeted Anti-cancer Drugs\nEstimate
 d primary completion: 25 November 2031. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pemigatinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05159245
URL:https://assetmemo.bio/drug/pemigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
